Samsung Biologics announced today that it completed the spinoff of its Samsung Bioepis unit to focus on leading as a pure-play CDMO. Following approval from its board, Samsung Biologics separated its investment and subsidiary management business to establish Samsung Epis Holdings. It finalized its Decision on Nov. 1 with plans to proceed with registration for…
Samsung Biologics signs $1.2B manufacturing deal with Asia-based pharmaceutical company
Samsung Biologics announced a contract manufacturing deal with an unnamed Asia-based pharmaceutical company worth $1.24 billion. According to a news release, it’s the largest contract signed by a single client. Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea. The contract runs through December 2037. With this agreement, the company’s accumulated…